By Matt Grossman

GlaxoSmithKline PLC and Vir Biotechnology Inc. have reached an agreement to supply Singapore's government with sotrovimab, an investigational single-dose antibody treatment for Covid-19

The treatment is for people with Covid-19 who don't require supplemental oxygen and who are at risk of progressing to severe Covid-19. GSK Singapore has submitted an application for interim authorization for the drug to Singapore's health authority.

A Phase 3 trial of the drug was stopped early by its data-monitoring committee because of strong evidence of efficacy, the companies said.

In May, the U.S. Food and Drug Administration authorized the drug for emergency use.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

06-30-21 0640ET